Universidad del Desarrollo

Now showing 1 - 6 of 6

Some of the metrics are blocked by your
consent settings
A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity
(Springer Science and Business Media LLC, 2025-12-15)
Constanza Méndez
;
Linmar Rodríguez-Guilarte
;
Pablo A. Palacios
;
Cristian Gutierrez-Vera
;
Francisca Román
1
Some of the metrics are blocked by your
consent settings
Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine
(Elsevier BV, 2025-08)
Yohana Martínez-Balboa
;
Linmar Rodríguez-Guilarte
;
Constanza Méndez
;
Mariana Ríos
;
Daniela B. Rivera
3Scopus© Citations 1
Some of the metrics are blocked by your
consent settings
Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN2COVID Phase I Randomized Trial
(2023)
Diego Garcia-Huidobro
;
Carolina Iturriaga
;
Guillermo Perez-Mateluna
;
Paula Fajuri
;
Nicolás Severino
Scopus© Citations 2 1
Some of the metrics are blocked by your
consent settings
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
(2021)
Susan M Bueno
;
Katia Abarca
;
GONZALEZ, PABLO
;
Nicolás M S Gálvez
;
Jorge A Soto
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports safety and immunogenicity results obtained for healthy Chilean adults aged ≥18 years in a phase 3 clinical trial.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Volunteers randomly received 2 doses of CoronaVac or placebo, separated by 2 weeks. A total of 434 volunteers were enrolled, 397 aged 18–59 years and 37 aged ≥60 years. Solicited and unsolicited adverse reactions were registered from all volunteers. Blood samples were obtained from a subset of volunteers and analyzed for humoral and cellular measures of immunogenicity.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The primary adverse reaction in the 434 volunteers was pain at the injection site, with a higher incidence in the vaccine than in the placebo arm. Adverse reactions observed were mostly mild and local. No severe adverse events were reported. The humoral evaluation was performed on 81 volunteers. Seroconversion rates for specific anti-S1-receptor binding domain (RBD) immunoglobulin G (IgG) were 82.22% and 84.44% in the 18–59 year age group and 62.69% and 70.37% in the ≥60 year age group, 2 and 4 weeks after the second dose, respectively. A significant increase in circulating neutralizing antibodies was detected 2 and 4 weeks after the second dose. The cellular evaluation was performed on 47 volunteers. We detected a significant induction of T-cell responses characterized by the secretion of interferon-γ (IFN-γ) upon stimulation with Mega Pools of peptides from SARS-CoV-2.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Immunization with CoronaVac in a 0–14 schedule in Chilean adults aged ≥18 years is safe, induces anti-S1-RBD IgG with neutralizing capacity, activates T cells, and promotes the secretion of IFN-γ upon stimulation with SARS-CoV-2 antigens.</jats:p> </jats:sec>
Scopus© Citations 75 1
Some of the metrics are blocked by your
consent settings
Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial
(2022)
Katia Abarca
;
Carolina Iturriaga
;
Marcela Urzúa
;
Nicole Le Corre
;
Augusto Pineda
<jats:p>Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®, an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe COVID-19 cases. We investigate the safety and non-inferiority of two immunization schedules of CoronaVac® in a non-inferiority trial in healthy adults. A total of 2302 healthy adults were enrolled at 8 centers in Chile and randomly assigned to two vaccination schedules, receiving two doses with either 14 or 28 days between each. The primary safety and efficacy endpoints were solicited adverse events (AEs) within 7 days of each dose, and comparing the number of cases of SARS-CoV-2 infection 14 days after the second dose between the schedules, respectively. The most frequent local AE was pain at the injection site, which was less frequent in participants aged ≥60 years. Other local AEs were reported in less than 5% of participants. The most frequent systemic AEs were headache, fatigue, and myalgia. Most AEs were mild and transient. There were no significant differences for local and systemic AEs between schedules. A total of 58 COVID-19 cases were confirmed, and all but 2 of them were mild. No differences were observed in the proportion of COVID-19 cases between schedules. CoronaVac® is safe, especially in ≥60-year-old participants. Both schedules protected against COVID-19 hospitalization.</jats:p>
1 2Scopus© Citations 9
Some of the metrics are blocked by your
consent settings
Prevalence of filaggrin loss‐of‐function variants in Chilean population with and without atopic dermatitis
(2021)
Geovanna V. Cárdenas
;
Carolina Iturriaga
;
Caroll D. Hernández
;
Macarena Tejos‐Bravo
;
Guillermo Pérez‐Mateluna
Scopus© Citations 11 2

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results